Key result
Paclitaxel DCB achieves 9-month vessel patency for in-stent restenosis in a severe CAV case.
Why the study?
Cardiac allograft vasculopathy is a leading cause of late graft failure with limited revascularization options and high rates of in-stent restenosis.
Does paclitaxel drug-coated balloon treatment prevent recurrent restenosis in a heart transplant recipient with in-stent restenosis due to cardiac allograft vasculopathy?
Case Report (n=1)
Does paclitaxel drug-coated balloon treatment prevent recurrent restenosis in a heart transplant recipient with in-stent restenosis due to cardiac allograft vasculopathy?
Drug-coated balloons may be a viable treatment option for in-stent restenosis in advanced cardiac allograft vasculopathy when additional stenting is undesirable.
Answers are grounded in this paper and cite their sources.
May offer an alternative to repeat stenting for in-stent restenosis in cardiac allograft vasculopathy; hypothesis-generating and requires prospective validation.
Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure with limited revascularization options and high rates of in-stent restenosis (ISR). This report details a 33-year-old heart transplant recipient with progressive CAV that underwent multiple prior revascularizations, including drug-eluting stents and coronary artery bypass grafting. He developed ISR of the right coronary artery stent, treated with paclitaxel drug-coated balloon (DCB) without further stenting. Follow-up at 3 and 9 months showed patent vessels without recurrent restenosis and preserved graft function. DCB may be a viable option for ISR in advanced CAV when additional stenting is undesirable. Larger studies are needed to define its long-term role.
No takes yet. Share an insight, caveat, or question.
Popoola et al. (2026) conducted a case report in Cardiac allograft vasculopathy with in-stent restenosis (n=1). Paclitaxel drug-coated balloon (DCB) was evaluated on Vessel patency and recurrent restenosis. Paclitaxel drug-coated balloon treatment for in-stent restenosis in a heart transplant recipient with severe cardiac allograft vasculopathy maintained vessel patency at 9 months follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: